Clinical trials: Retinopathy, Diabetic
Macular Edema
Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID EAST (NCT01783886)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Macular Laser Photocoagulation
- Where
- 25 sites in China, Hong Kong and 2 more
- Volunteers
- 381 people
- Sponsor
- Bayer
Diabetes, Macular Edema
Research Study in Patients With Persistent Macular Edema
The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods.
- Conditions
- Diabetes, Macular Edema, Diabetic Retinopathy, Retinal Disease
- Trial name
- NCT00035906
- Testing
- DEX PS DDS®
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Allergan
Diabetic Retinopathy, Macular Oedema
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
This study evaluates a new investigational treatment regimen of three consecutive monthly doses of ranibizumab followed by an as-needed treatment regimen, with monthly follow-up for the first three months then two-monthly…
- Trial name
- RELIGHT (NCT01257815)
- Testing
- Ranibizumab
- Where
- 15 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.
Diabetic retinopathy (DR) is a common complication of diabetes mellitus that leads to loss of vision and blindness among working age adults.
- Trial name
- NCT04552600
- Testing
- Nuvastatic
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Natureceuticals Sdn Bhd
Diabetic Retinopathy
Assessment of EyeArt Performance With Retinal Cameras
The study evaluates the performance of the EyeArt system for detecting diabetic retinopathy from images captured using retinal cameras and operators.
- Trial name
- NCT04984200
- Testing
- Retinal imaging, Mydriatic Agent
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- Eyenuk, Inc.
Macular Edema, Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
This was an open-label, multi-center, FIH study with a single ascending dose (SAD) design that assessed the safety, tolerability and pharmacokinetics (PK) of a single IVT dose of MHU650 in up to 24 participants with macular edema.
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Trial name
- NCT04635800
- Testing
- MHU650
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Diabetic Retinopathy
Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images
AEYE-DS is a software device developed to increase compliance with diabetic retinopathy screening by automatically detecting more-than-mild diabetic retinopathy from digital funduscopic images using AI-based software.
- Trial name
- NCT05857943
- Testing
- AEYE-DS Software
- Where
- 3 sites in United States
- Volunteers
- 363 people
- Sponsor
- AEYE Health Inc
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
- Trial name
- NCT03835884
- Testing
- AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Aerie Pharmaceuticals
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705607
- Testing
- MK-8748, Aflibercept
- Where
- 19 sites in United States
- Volunteers
- 1,104 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Retinopathy
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248157
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Intraocular Inflammation, Suspected Endophthalmitis
A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
Specific study objectives include: To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually).
- Trial name
- NCT05791695
- Testing
- Non Applicable
- Where
- United States
- Volunteers
- 155,413 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Proliferative Diabetic Retinopathy
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
A Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.
- Trial name
- NCT02435862
- Testing
- 1.0mg Luminate®, 2.0mg Luminate®, 3.0mg Luminate®
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Allegro Ophthalmics, LLC
Macular Edema
Special Drug Use Investigation of EYLEA for Diabetic Macular Edema
The objectives of this study are to investigate the safety and effectiveness of EYLEA
- Trial name
- NCT02425501
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Japan
- Volunteers
- 646 people
- Sponsor
- Bayer
Macular Edema
Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).
- Trial name
- NCT01492400
- Testing
- dexamethasone Intravitreal Implant, ranibizumab
- Where
- 13 sites in United States, Belgium and 10 more
- Volunteers
- 363 people
- Sponsor
- Allergan
Diabetic Macular Oedema
Noctura400 Treatment for Diabetic Retinopathy (CANDLE)
In this study, the investigators aim to use light masks (Noctura 400) to test the hypothesis that preventing the dark adaptation and associated hypoxia of the rods in the eye could in turn prevent or halt the progression of…
- Trial name
- CANDLE (NCT02207712)
- Testing
- Noctura 400 Eye Mask, Ranibizumab
- Where
- 18 sites in United Kingdom
- Volunteers
- 252 people
- Sponsor
- PolyPhotonix Medical
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
- Trial name
- DME (NCT05698329)
- Testing
- AIV007
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- AiViva BioPharma, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma…
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Macular Degeneration
- Trial name
- NCT06305416
- Testing
- Ranibizumab 10mg/ml Injection, Lucentis
- Where
- Bangladesh
- Volunteers
- 70 people
- Sponsor
- Incepta Pharmaceuticals Ltd
Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the…
- Conditions
- Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME)
- Trial name
- NCT02585401
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetic Macular Edema
To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of Chinese patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- KINGLET (NCT04058067)
- Testing
- Brolucizumab, Aflibercept
- Where
- 24 sites in China
- Volunteers
- 266 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
To compare the progression of diabetic retinopathy in type 2 diabetic patients with mild-to-moderate diabetic retinopathy treated with insulin glargine vs NPH human insulin.
- Trial name
- NCT00174824
- Testing
- Insulin glargine
- Where
- 2 sites in United States, Canada
- Volunteers
- 1,024 people
- Sponsor
- Sanofi